Brief: Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment In Phase 1B Study In Patients With Platinum-Resistant Arid1a-Mutated Ovarian Cancer
14/11/2024 12:25
Nov 14 (Reuters) - Nuvectis Pharma Inc NVCT.O :
* NUVECTIS PHARMA REPORTS ENCOURAGING NXP800 INTERIM DATA
SUPPORTING ONGOING ENROLLMENT IN PHASE 1B STUDY IN PATIENTS WITH
PLATINUM-RESISTANT ARID1A-MUTATED OVARIAN CANCER
* NUVECTIS PHARMA INC - ADDITIONAL PHASE 1B CLINICAL DATA
EXPECTED
IN Q2 2025
Source text: urn:newsml:reuters.com:*:nGNX6ztMsL
Further company coverage: NVCT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nuvectis Pharma
See all newsNuvectis Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Nuvectis Pharma Inc expected to post a loss of 26 cents a share - Earnings Preview
Brief: Ciprocopan (NXP100) Receives Marketing Approval In China For The Treatment Of Patients With PNH Previously Untreated With Complement Inhibitors
U.S. STOCKS ON THE MOVE-Chip stocks, Unicycive, Roblox
U.S. STOCKS ON THE MOVE-AMD, Roblox, Olin